ABCB9 p.Lys545Met
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 16554024
[PubMed]
Ohashi-Kobayashi A et al: "Examination of drug resistance activity of human TAP-like (ABCB9) expressed in yeast."
No.
Sentence
Comment
23
For YEpTAPL(K546M)His, the DraIII-NgoMI fragment from phTAPL(K545M) plasmid, which has a mutation of Lys (AAG) at position 546 to Met (AtG) by PCR technique reported by Imai et al. [11] using mutated primers, was excised and replaced by the DraIII-NgoMI fragment of YEpTAPLHis.
X
ABCB9 p.Lys545Met 16554024:23:61
status: NEW83 For this purpose, we constructed an expression plasmid for hTAPL(K545M) harboring mutation in the Walker A motif, and it was introduced into yeast.
X
ABCB9 p.Lys545Met 16554024:83:65
status: NEWX
ABCB9 p.Lys545Met 16554024:83:95
status: NEW84 Prior to drug sensitivity assay, we determined the ATP-binding capabilities of hTAPL and hTAPL(K545M).
X
ABCB9 p.Lys545Met 16554024:84:20
status: NEWX
ABCB9 p.Lys545Met 16554024:84:95
status: NEW85 Expression of hTAPL(K545M) was similar in amounts compared with that of hTAPL by means of Western blotting.
X
ABCB9 p.Lys545Met 16554024:85:20
status: NEW87 3A and B, hTAPL bound ATP-agarose, whereas hTAPL(K545M) did not.
X
ABCB9 p.Lys545Met 16554024:87:49
status: NEW94 TAPL p.c. P P S S - + - + (ATP) - + - + (ATP) TAPL K545M p.c. P P S S hTAPL(K545M) Raf61 hMDR hTAPL 5103 1103 2102 4101 8100 100µM valinomycin (cells/µl) A B Fig. 3.
X
ABCB9 p.Lys545Met 16554024:94:51
status: NEWX
ABCB9 p.Lys545Met 16554024:94:76
status: NEW96 (A) ATP-binding activity was examined on hTAPL and hTAPL(K545M) (mutation in Walker A motif).
X
ABCB9 p.Lys545Met 16554024:96:34
status: NEWX
ABCB9 p.Lys545Met 16554024:96:57
status: NEW97 Plasmid containing hTAPL or hTAPL(K545M) was transfected to yeast and the membrane fractions were prepared.
X
ABCB9 p.Lys545Met 16554024:97:34
status: NEW101 (B) Sensitivity to valinomycin was examined on the yeast cells expressing hTAPL, hTAPL(K545M), or carrying control empty vector.
X
ABCB9 p.Lys545Met 16554024:101:87
status: NEW103 Next, we examined valinomycin sensitivity of the yeast cell expressing hTAPL(K545M).
X
ABCB9 p.Lys545Met 16554024:103:77
status: NEW82 For this purpose, we constructed an expression plasmid for hTAPL(K545M) harboring mutation in the Walker A motif, and it was introduced into yeast.
X
ABCB9 p.Lys545Met 16554024:82:65
status: NEW86 3A and B, hTAPL bound ATP-agarose, whereas hTAPL(K545M) did not.
X
ABCB9 p.Lys545Met 16554024:86:49
status: NEW93 TAPL p.c. P P S S - + - + (ATP) - + - + (ATP) TAPL K545M p.c. P P S S hTAPL(K545M) Raf61 hMDR hTAPL 5 10 3 1 10 3 2 10 2 4 10 1 8 10 0 100&#b5;M valinomycin (cells/&#b5;l) A B Fig. 3.
X
ABCB9 p.Lys545Met 16554024:93:51
status: NEWX
ABCB9 p.Lys545Met 16554024:93:76
status: NEW95 (A) ATP-binding activity was examined on hTAPL and hTAPL(K545M) (mutation in Walker A motif).
X
ABCB9 p.Lys545Met 16554024:95:57
status: NEW100 (B) Sensitivity to valinomycin was examined on the yeast cells expressing hTAPL, hTAPL(K545M), or carrying control empty vector.
X
ABCB9 p.Lys545Met 16554024:100:87
status: NEW102 Next, we examined valinomycin sensitivity of the yeast cell expressing hTAPL(K545M).
X
ABCB9 p.Lys545Met 16554024:102:77
status: NEW